Volume 5, Issue 6, Pages (June 2002)

Slides:



Advertisements
Similar presentations
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Induction of Rapid and Highly Efficient Expression.
Advertisements

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Up-regulation of Brain-Derived Neurotrophic Factor.
François Tremblay, Jenna Waterhouse, Janette Nason, Wilhelmina Kalt 
Volume 17, Issue 4, Pages (April 2009)
Invest. Ophthalmol. Vis. Sci ;54(9): doi: /iovs Figure Legend:
From: Efficient Gene Transfer into Retinal Cells Using Adenoviral Vectors: Dependence on Receptor Expression Invest. Ophthalmol. Vis. Sci ;45(6):
Rap1 GTPase Inhibits Tumor Necrosis Factor-α–Induced Choroidal Endothelial Migration via NADPH Oxidase– and NF-κB–Dependent Activation of Rac1  Haibo.
From: Neuroprotective Effects of Transcription Factor Brn3b in an Ocular Hypertension Rat Model of Glaucoma Invest. Ophthalmol. Vis. Sci ;56(2):
TRPV1: Contribution to Retinal Ganglion Cell Apoptosis and Increased Intracellular Ca2+ with Exposure to Hydrostatic Pressure Invest. Ophthalmol. Vis.
Volume 3, Issue 5, Pages (May 2001)
Khanh-Nhat Tran-Viet, Caldwell Powell, Veluchamy A
Volume 8, Issue 2, Pages (August 2003)
Volume 26, Issue 2, Pages (May 2000)
Volume 21, Issue 6, Pages (June 2013)
Molecular Therapy - Nucleic Acids
Optic neuritis: A mechanistic view
Activation of the Extracellular Signal-Regulated Kinase 1/2 Pathway by AAV Gene Transfer Protects Retinal Ganglion Cells in Glaucoma  Yu Zhou, Vincent.
Molecular Therapy - Methods & Clinical Development
Volume 22, Issue 1, Pages (January 2014)
EGF Upregulates, Whereas TGF-β Downregulates, the Hyaluronan Synthases Has2 and Has3 in Organotypic Keratinocyte Cultures: Correlations with Epidermal.
Volume 22, Issue 1, Pages (January 2014)
Volume 21, Issue 10, Pages (October 2013)
Adeno-Associated Viral Vector-Mediated mTOR Inhibition by Short Hairpin RNA Suppresses Laser-Induced Choroidal Neovascularization  Tae Kwann Park, Si.
Volume 25, Issue 1, Pages (January 2017)
Volume 73, Issue 3, Pages (February 2012)
Volume 4, Issue 6, Pages (December 2001)
Volume 25, Issue 3, Pages (March 2017)
Regulation of α-Synuclein Expression by Poly (ADP Ribose) Polymerase-1 (PARP-1) Binding to the NACP-Rep1 Polymorphic Site Upstream of the SNCA Gene  Ornit.
Volume 31, Issue 6, Pages (September 2001)
Volume 19, Issue 2, Pages (February 2011)
Volume 15, Issue 6, Pages (March 2005)
Volume 18, Issue 4, Pages (April 2010)
The retinal pigmented epithelium is required for development and maintenance of the mouse neural retina  Sophie M. Raymond, Ian J. Jackson  Current Biology 
Volume 4, Issue 5, Pages (November 2001)
Volume 94, Issue 6, Pages e4 (June 2017)
Molecular Therapy - Methods & Clinical Development
Volume 3, Issue 4, Pages (April 2001)
Volume 5, Issue 6, Pages (June 2002)
Strong Promoters Are the Key to Highly Efficient, Noninflammatory and Noncytotoxic Adenoviral-Mediated Transgene Delivery into the Brain in Vivo  Christian.
Spatially and Temporally Regulated NRF2 Gene Therapy Using Mcp-1 Promoter in Retinal Ganglion Cell Injury  Kosuke Fujita, Koji M. Nishiguchi, Yukihiro.
Molecular Therapy - Methods & Clinical Development
Volume 26, Issue 2, Pages (May 2000)
Notch Receptor Activation Inhibits Oligodendrocyte Differentiation
Volume 17, Issue 5, Pages (May 2009)
Volume 25, Issue 8, Pages (August 2017)
Computer-assisted Hydrodynamic Gene Delivery
Volume 23, Issue 2, Pages (February 2015)
Improved Retinal Transduction In Vivo and Photoreceptor-specific Transgene Expression Using Adenovirus Vectors With Modified Penton Base  Siobhan M Cashman,
Volume 19, Issue 6, Pages (June 2011)
Molecular Therapy - Methods & Clinical Development
Volume 17, Issue 12, Pages (December 2009)
Volume 19, Issue 2, Pages (February 2011)
Volume 13, Issue 3, Pages (March 2006)
Volume 92, Issue 6, Pages (December 2016)
Volume 8, Issue 2, Pages (August 2003)
J.M.I. Malik, Z. Shevtsova, M. Bähr, S. Kügler  Molecular Therapy 
Volume 21, Issue 10, Pages (October 2013)
Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery  Laura Garcia-Garcia, Sergio Recalde,
Volume 20, Issue 4, Pages (April 2012)
Volume 19, Issue 9, Pages (September 2011)
Reporter Gene Transfer Induces Apoptosis in Primary Cortical Neurons
Keratinocyte-Derived Granulocyte-Macrophage Colony Stimulating Factor Accelerates Wound Healing: Stimulation of Keratinocyte Proliferation, Granulation.
Volume 25, Issue 4, Pages (April 2017)
Volume 9, Issue 2, Pages (February 2004)
Volume 27, Issue 11, Pages e3 (June 2019)
Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery  Laura Garcia-Garcia, Sergio Recalde,
Fig. 8. Electron micrographs taken from 8-week glaucoma retina
Fig. 7. Apoptotic cell death was evaluated via TUNEL
Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter  Lawrence E Ostrowski, James R Hutchins,
The predicted new isoform of PCP2 is expressed in retinal ON bipolar cells. The predicted new isoform of PCP2 is expressed in retinal ON bipolar cells.
Presentation transcript:

Volume 5, Issue 6, Pages 780-787 (June 2002) Baculoviral IAP Repeat-Containing-4 Protects Optic Nerve Axons in a Rat Glaucoma Model  Stuart J. McKinnon, Donna M. Lehman, N.Grace Tahzib, Nancy L. Ransom, Herbert A. Reitsamer, Peter Liston, Eric LaCasse, Qiuhong Li, Robert G. Korneluk, William W. Hauswirth  Molecular Therapy  Volume 5, Issue 6, Pages 780-787 (June 2002) DOI: 10.1006/mthe.2002.0608 Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 1 Human BIRC4 mRNA is upregulated in rat retinas 1 month after unilateral intraocular injection of AAV-BIRC4. Varying amounts of template RNA (25, 50, 100, or 200 ng) were used for each treated and control eye. Expression levels of human BIRC4 mRNA were normalized relative to endogenous rat GAPDH for each sample. Fold-increases in human BIRC4 mRNA expression for three transduced eyes are given relative to untreated control eyes. Error bars, standard deviation. Molecular Therapy 2002 5, 780-787DOI: (10.1006/mthe.2002.0608) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 2 Transgene protein expression is upregulated in the RGC layer and ciliary body 1 month after unilateral intraocular injection of AAV constructs. (A) GFP expression is seen in individual RGCs with high transfection efficiencies. Occasional labeling of bipolar cells (arrow) is also seen. (B, C) Human BIRC4 was detected in the ciliary body of transduced eyes (B) but not in control eyes (C). (D) Western immunoblots of retinal extracts from AAV-BIRC4 transduced eyes (+) and paired control eyes (-) were probed with antibody directed against human BIRC4. Upregulation of BIRC4 is seen in the two transduced eyes when compared with controls. ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; RGC, retinal ganglion cell layer. Scale bars (A–C), 50 μm. Molecular Therapy 2002 5, 780-787DOI: (10.1006/mthe.2002.0608) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 3 Intraocular pressure (IOP) characteristics of rat eyes with ocular hypertension produced by sclerosis of aqueous humor outflow channels with hypertonic saline (2.0 M). (A) For a representative included rat, a peak IOP difference of 13.6 mm over control is seen at week 10. The gray area between the hypertensive and control eye constitutes the IOP-integral difference, with a value of 463.6 mm-days. Animals with no elevation of IOP in the treated eye were excluded from the analysis. (B) A representative excluded rat in this group had an IOP-integral difference of –336.4, indicating profound hypotony. Arrows (far right) denote whether the IOPs were elevated (A) or depressed (B) in the treated eye relative to control. (C) Cumulative IOP-integral differences for each group are plotted for each time point, and are seen to increase over the duration of IOP exposure. The mean cumulative IOP exposure for the BIRC4 group is statistically significantly lower than the GFP group, but not the BSS group. Molecular Therapy 2002 5, 780-787DOI: (10.1006/mthe.2002.0608) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 4 Optic nerves subjected to ocular hypertension show morphological changes due to optic nerve axon loss. (A, B) Sections of rat eye cup that include the optic nerve were obtained from paired hypertensive (A) and control (B) eyes and stained with hematoxylin and eosin. Axon loss and posterior deformation (arrowhead) of the nerve head are seen in the hypertensive eye in a manner analogous to the “cupping” seen in human glaucoma. (C, D) An optic nerve cross section from a representative hypertensive eye injected with AAV-GFP (C) compared with the paired control (D) shows gliosis and profound axon loss. (E, F) The optic nerve from a representative hypertensive eye injected with AAV-BIRC4 shows relative protection of optic nerve axons compared with the AAV-GFP hypertensive eye (C) and paired control eye (F). Sections (C–F) have been stained with 1% toluidine blue. (G, H) Fluorescent TUNEL assay of ocular hypertensive retinas from AAV-GFP and AAV-BIRC4 groups. TUNEL-stained RGCs are prominent in an AAV-GFP-treated retina (G), whereas only background fluorescence is noted (arrowhead) in RGCs in the AAV-BIRC4-treated retina (H). RPE, retinal pigment epithelium; ONL, outer nuclear layer; RGC, retinal ganglion cell layer. Scale bars: (A, B) 200 μm; (C–F) 10 μm; (G, H) 50 μm. Molecular Therapy 2002 5, 780-787DOI: (10.1006/mthe.2002.0608) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 5 Optic nerve axon survival in the AAV-BIRC4, AAV-GFP, and BSS groups. (A) Box plots of the three groups show percent axon survivals (hypertensive versus control) for individual rats. The distribution of axon survivals in the BIRC4 group is wider than those of the GFP and BSS groups, with more animals in the BIRC4 group showing greater than 30% survival. Box, quartiles; midline, median; error bars, 95% confidence interval. (B) Percent axon losses for animals in the BIRC4, GFP, and BSS groups are separately plotted against IOP exposure as expressed by the IOP-integral difference. Linear regressions for each of the three groups show that for moderate IOP exposures of less than 400 mm-days, AAV-BIRC4 treatment seems to potentiate greater axon survival than either the AAV-GFP or BSS treated groups. Molecular Therapy 2002 5, 780-787DOI: (10.1006/mthe.2002.0608) Copyright © 2002 American Society for Gene Therapy Terms and Conditions